08.02.48, Papzimeos (zopapogene imadenovec-drba)
Independence Blue Cross has published a new medical policy (08.02.48) effective 08/03/2026 covering Papzimeos (zopapogene imadenovec-drba) for treatment of recurrent respiratory papillomatosis (RRP) in adults. Coverage is limited to a single lifetime treatment course of four injections over 12 weeks when specific clinical criteria are met, including confirmed HPV 6/11 diagnosis, prior surgical intervention, and prescriber attestation of surgical debulking protocols. Billing teams must implement prior authorization requirements and ensure claims are submitted only when all medical necessity criteria are documented.